News & Blog

News & Blog

News | Jun 17 2026

Press Release & Community Statement: Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Industry News
News | May 29 2026

Community Letter: Update from PTC Therapeutics

Industry News
News | May 15 2026

Press release and community statement: Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Industry News
News | Aug 19 2025

Press Release & Community Statement: PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA

Industry News
News | Aug 7 2025

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

Industry News
News | Mar 24 2025

Press Release & Community Update: Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Industry News
News | Mar 24 2025

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Industry News
News | Feb 19 2025

Press Release & Community Statement: PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich’s Ataxia

Industry News
News | Feb 4 2025

Letter to the FA Community from Astellas Pharma

Industry News
News | Jan 29 2025

Webinar Recording: PTC Therapeutics Vatiquinone Program January 2025 Update

FARA News | Industry News
News | Jan 23 2025

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

Industry News
News | Jan 21 2025

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Industry News